Temoporfin

PreclinicalSmall molecule

UUniversity of Arkansas

Temoporfin is one of 15 small molecule programs targeting Oropharyngeal Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Oropharyngeal CancerWithdrawn

Oropharyngeal CancerPreclinical

Withdrawn

Competition

Competitive Landscape

19 competitors in Oropharyngeal Cancer

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 3

1 2

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

9 3

Taxol

Teva

Phase 2

3 4

Beyfortus

BeiGene

Phase 2

1 5

Paraplatin

AAvyxa

Phase 2

4 6

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 2

1 7

Fludara

Sanofi

Phase 1

1 8

Balstilimab

AAgenus Inc.

Phase 2

1 9

Cytoxan

BBaxter Healthcare Corporation

Phase 1

1 10

Xentuzumab

SSyndax Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Photodynamic Therapy During Surgery in Treating Patients With Non-small Cell Lung Cancer That Can Be Removed by Surgery

Completed·RRoswell Park Cancer Institute·Phase 1·NCT01854684·8 enrolled

Lung Cancer1 trial

Photodynamic Therapy (PDT) With Temoporfin for Non-Resectable Non-Small-Cell Lung Cancer

Withdrawn·UUniversity of Arkansas·Phase 1·NCT01637376

Head and Neck Cancer1 trial

Photodynamic Therapy in Treating Patients With Recurrent, Refractory, or Second Primary Head and Neck Cancer That Cannot Be Treated With Surgery or Radiation Therapy

Unknown status·QQuintiles, Inc.·Phase 2·NCT00003856·75 enrolled

Bile Duct Carcinoma1 trial

Single-arm Study of Photodynamic Laser Therapy Using Foscan for Non-curatively-resectable Bile Duct Carcinoma

Unknown status·—·Phase 2·NCT01016002·35 enrolled

Oropharyngeal Cancer1 trial

Photodynamic Therapy Using Temoporfin Before Surgery in Treating Patients With Recurrent Oral Cavity or Oropharyngeal Cancer

Withdrawn·RRoswell Park Cancer Institute·N/A·NCT01718223

2 more indications

Advanced Head and Neck Cancer1 trial

Interstitial Photodynamic Therapy (PDT) With Temoporfin for Advanced Head and Neck Cancers

Terminated·UUniversity of Arkansas·Phase 2·NCT01415986·1 enrolled

Bile Duct Cancer1 trial

Safety and Tumoricidal Effect of Low Dose Foscan PDT in Patients With Inoperable Bile Duct Cancers

Completed·—·Phase 2·NCT03003065·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Temoporfin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Temoporfin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Temoporfin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Arkansas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Arkansas

Temoporfin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Lung Cancer1 trial

Head and Neck Cancer1 trial

Bile Duct Carcinoma1 trial

Oropharyngeal Cancer1 trial

Advanced Head and Neck Cancer1 trial

Bile Duct Cancer1 trial

References

Drug Info

Quick Facts

Related News